基于综合证据链的中药疗效评价(ef - iec)的实证研究

IF 14.7 1区 医学 Q1 PHARMACOLOGY & PHARMACY
Ye Luo , Xu Zhao , Ruilin Wang , Xiaoyan Zhan , Tianyi Zhang , Tingting He , Jing Jing , Jianyu Li , Fengyi Li , Ping Zhang , Junling Cao , Jinfa Tang , Zhijie Ma , Tingming Shen , Shuanglin Qin , Ming Yang , Jun Zhao , Zhaofang Bai , Jiabo Wang , Aiguo Dai , Xiaohe Xiao
{"title":"基于综合证据链的中药疗效评价(ef - iec)的实证研究","authors":"Ye Luo ,&nbsp;Xu Zhao ,&nbsp;Ruilin Wang ,&nbsp;Xiaoyan Zhan ,&nbsp;Tianyi Zhang ,&nbsp;Tingting He ,&nbsp;Jing Jing ,&nbsp;Jianyu Li ,&nbsp;Fengyi Li ,&nbsp;Ping Zhang ,&nbsp;Junling Cao ,&nbsp;Jinfa Tang ,&nbsp;Zhijie Ma ,&nbsp;Tingming Shen ,&nbsp;Shuanglin Qin ,&nbsp;Ming Yang ,&nbsp;Jun Zhao ,&nbsp;Zhaofang Bai ,&nbsp;Jiabo Wang ,&nbsp;Aiguo Dai ,&nbsp;Xiaohe Xiao","doi":"10.1016/j.apsb.2024.12.024","DOIUrl":null,"url":null,"abstract":"<div><div>Addressing the enduring challenge of evaluating traditional Chinese medicines (TCMs), the integrated evidence chain-based effectiveness evaluation of TCMs (Eff-iEC) has emerged. This paper explored its capacity through a demonstration study that evaluated the effectiveness evidence of six commonly used anti-hepatic fibrosis Chinese patent medicines (CPMs), including Biejiajian Pill (BP), Dahuang Zhechong Pill (DZP), Biejia Ruangan Compound (BRC), Fuzheng Huayu Capsule (FHC), Anluo Huaxian Pill (AHP), and Heluo Shugan Capsule (HSC), using both Eff-iEC and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system. The recognition of these CPMs within the TCM academic community was also assessed through their inclusion in relevant medical documents. Results showed that the evidence of BRC and FHC received higher assessments in both Eff-iEC and GRADE system, while the assessments for others varied. Analysis of community recognition revealed that Eff-iEC more accurately reflects the clinical value of these CPMs, exhibiting superior evaluative capabilities. By breaking through the conventional pattern of TCMs effectiveness evaluation, Eff-iEC offers a novel epistemology that better aligns with the clinical realities and reasoning of TCMs, providing a coherent methodology for clinical decision-making, new drug evaluations, and health policy formulation.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"15 2","pages":"Pages 909-918"},"PeriodicalIF":14.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Integrated evidence chain-based effectiveness evaluation of traditional Chinese medicines (Eff-iEC): A demonstration study\",\"authors\":\"Ye Luo ,&nbsp;Xu Zhao ,&nbsp;Ruilin Wang ,&nbsp;Xiaoyan Zhan ,&nbsp;Tianyi Zhang ,&nbsp;Tingting He ,&nbsp;Jing Jing ,&nbsp;Jianyu Li ,&nbsp;Fengyi Li ,&nbsp;Ping Zhang ,&nbsp;Junling Cao ,&nbsp;Jinfa Tang ,&nbsp;Zhijie Ma ,&nbsp;Tingming Shen ,&nbsp;Shuanglin Qin ,&nbsp;Ming Yang ,&nbsp;Jun Zhao ,&nbsp;Zhaofang Bai ,&nbsp;Jiabo Wang ,&nbsp;Aiguo Dai ,&nbsp;Xiaohe Xiao\",\"doi\":\"10.1016/j.apsb.2024.12.024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Addressing the enduring challenge of evaluating traditional Chinese medicines (TCMs), the integrated evidence chain-based effectiveness evaluation of TCMs (Eff-iEC) has emerged. This paper explored its capacity through a demonstration study that evaluated the effectiveness evidence of six commonly used anti-hepatic fibrosis Chinese patent medicines (CPMs), including Biejiajian Pill (BP), Dahuang Zhechong Pill (DZP), Biejia Ruangan Compound (BRC), Fuzheng Huayu Capsule (FHC), Anluo Huaxian Pill (AHP), and Heluo Shugan Capsule (HSC), using both Eff-iEC and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system. The recognition of these CPMs within the TCM academic community was also assessed through their inclusion in relevant medical documents. Results showed that the evidence of BRC and FHC received higher assessments in both Eff-iEC and GRADE system, while the assessments for others varied. Analysis of community recognition revealed that Eff-iEC more accurately reflects the clinical value of these CPMs, exhibiting superior evaluative capabilities. By breaking through the conventional pattern of TCMs effectiveness evaluation, Eff-iEC offers a novel epistemology that better aligns with the clinical realities and reasoning of TCMs, providing a coherent methodology for clinical decision-making, new drug evaluations, and health policy formulation.</div></div>\",\"PeriodicalId\":6906,\"journal\":{\"name\":\"Acta Pharmaceutica Sinica. B\",\"volume\":\"15 2\",\"pages\":\"Pages 909-918\"},\"PeriodicalIF\":14.7000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Pharmaceutica Sinica. B\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2211383524004817\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmaceutica Sinica. B","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211383524004817","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

针对中药疗效评价的长期挑战,基于证据链的中药疗效综合评价(ef - iec)应运而生。本文通过对六种常用抗肝纤维化中成药(包括别家健丸(BP)、大黄止血丸(DZP)、别家润肝复方(BRC)、妇正化瘀胶囊(FHC)、安络化仙丸(AHP)、和络舒肝胶囊(HSC)的有效性证据进行实证评价,采用effe - iec和推荐、评估、开发和评价分级(GRADE)系统,探讨其能力。通过将这些cpm纳入相关医学文献,评估了中医学术界对这些cpm的认可程度。结果表明,BRC和FHC证据在ef - iec和GRADE体系中均获得较高的评价,而其他证据的评价差异较大。社区认知分析显示,ef - iec更准确地反映了这些cpm的临床价值,表现出更好的评估能力。通过突破传统的中药疗效评估模式,effe - iec提供了一种更符合中医临床实际和推理的新型认识论,为临床决策、新药评估和卫生政策制定提供了一种连贯的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Integrated evidence chain-based effectiveness evaluation of traditional Chinese medicines (Eff-iEC): A demonstration study

Integrated evidence chain-based effectiveness evaluation of traditional Chinese medicines (Eff-iEC): A demonstration study
Addressing the enduring challenge of evaluating traditional Chinese medicines (TCMs), the integrated evidence chain-based effectiveness evaluation of TCMs (Eff-iEC) has emerged. This paper explored its capacity through a demonstration study that evaluated the effectiveness evidence of six commonly used anti-hepatic fibrosis Chinese patent medicines (CPMs), including Biejiajian Pill (BP), Dahuang Zhechong Pill (DZP), Biejia Ruangan Compound (BRC), Fuzheng Huayu Capsule (FHC), Anluo Huaxian Pill (AHP), and Heluo Shugan Capsule (HSC), using both Eff-iEC and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system. The recognition of these CPMs within the TCM academic community was also assessed through their inclusion in relevant medical documents. Results showed that the evidence of BRC and FHC received higher assessments in both Eff-iEC and GRADE system, while the assessments for others varied. Analysis of community recognition revealed that Eff-iEC more accurately reflects the clinical value of these CPMs, exhibiting superior evaluative capabilities. By breaking through the conventional pattern of TCMs effectiveness evaluation, Eff-iEC offers a novel epistemology that better aligns with the clinical realities and reasoning of TCMs, providing a coherent methodology for clinical decision-making, new drug evaluations, and health policy formulation.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica. B Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
CiteScore
22.40
自引率
5.50%
发文量
1051
审稿时长
19 weeks
期刊介绍: The Journal of the Institute of Materia Medica, Chinese Academy of Medical Sciences, and the Chinese Pharmaceutical Association oversees the peer review process for Acta Pharmaceutica Sinica. B (APSB). Published monthly in English, APSB is dedicated to disseminating significant original research articles, rapid communications, and high-quality reviews that highlight recent advances across various pharmaceutical sciences domains. These encompass pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis, and pharmacokinetics. A part of the Acta Pharmaceutica Sinica series, established in 1953 and indexed in prominent databases like Chemical Abstracts, Index Medicus, SciFinder Scholar, Biological Abstracts, International Pharmaceutical Abstracts, Cambridge Scientific Abstracts, and Current Bibliography on Science and Technology, APSB is sponsored by the Institute of Materia Medica, Chinese Academy of Medical Sciences, and the Chinese Pharmaceutical Association. Its production and hosting are facilitated by Elsevier B.V. This collaborative effort ensures APSB's commitment to delivering valuable contributions to the pharmaceutical sciences community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信